Payment overview · 2025
General Payments
$89.13
4 reported records · 4 companies
Healthcare provider profile · identity verified
Teodora Brose
Allopathic & Osteopathic Physicians|Family Medicine · APPOMATTOX, VA · NPI 1730594029
Verified facts
What the public records show
CMS Open Payments records show Teodora Brose received $89.13 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.03 | 32.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.92 | 26.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.71 | 24.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.47 | 16.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.13 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 212 |
| Lisinopril | Lisinopril | 424 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 106 |
| Omeprazole | Omeprazole | 325 | 83 |
| Metformin Hcl | Metformin Hcl | 311 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 74 |
| Gabapentin | Gabapentin | 216 | 53 |
| Ozempic | Semaglutide | 195 | 29 |
| Furosemide | Furosemide | 194 | 59 |
| Losartan Potassium | Losartan Potassium | 181 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 46 |
| Alprazolam | Alprazolam | 146 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 32 |
| Sertraline Hcl | Sertraline Hcl | 118 | 37 |
| Simvastatin | Simvastatin | 111 | 28 |
| Allopurinol | Allopurinol | 104 | 24 |
| Carvedilol | Carvedilol | 102 | 28 |
| Montelukast Sodium | Montelukast Sodium | 99 | 30 |
| Potassium Chloride | Potassium Chloride | 98 | 28 |
| Famotidine | Famotidine | 96 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 26 |
| Alendronate Sodium | Alendronate Sodium | 83 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 25 |
| Prednisone | Prednisone | 81 | 34 |
| Eliquis | Apixaban | 79 | 16 |
| Bupropion Xl | Bupropion Hcl | 78 | 23 |
| Mounjaro | Tirzepatide | 78 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Glimepiride | Glimepiride | 74 | 22 |
| Metformin Hcl Er | Metformin Hcl | 73 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Buspirone Hcl | Buspirone Hcl | 67 | 14 |
| Trazodone Hcl | Trazodone Hcl | 66 | 19 |
| Farxiga | Dapagliflozin Propanediol | 64 | 11 |
| Mirtazapine | Mirtazapine | 64 | 11 |
| Januvia | Sitagliptin Phosphate | 63 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 15 |
| Trulicity | Dulaglutide | 63 | 11 |
| Atenolol | Atenolol | 61 | 17 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Glipizide Er | Glipizide | 56 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Cephalexin | Cephalexin | 53 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 16 |
| Jardiance | Empagliflozin | 52 | 12 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Nystatin | Nystatin | 51 | 19 |
| Tramadol Hcl | Tramadol Hcl | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 16 |
| Clonazepam | Clonazepam | 47 | 12 |
| Naproxen | Naproxen | 46 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Donepezil Hcl | Donepezil Hcl | 43 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 11 |
| Glipizide | Glipizide | 41 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 12 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Diazepam | Diazepam | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 13 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | 12 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Epinephrine | Epinephrine | 22 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Blisovi Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.13 · 4 records | ABBVIE INC. | EVENITY, INSPIRE, NURTEC ODT, QULIPTA, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error